# Impedans

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/impedans

- Industry: Biotechnology
- Headquarters: Dublin, Ireland
- Website: www.impedans.com
- Total disclosed funding: $4.5M
- Latest round: Series B (Nov 30, 2021)
- Investors on record: 3

## About

Impedans is an innovative company specializing in high-precision sensors and diagnostic solutions in plasma technology, serving clients in diverse sectors including semiconductor manufacturing and research.Founded in 2004 and headquartered in Dublin, Ireland, Impedans focuses on providing advanced diagnostic tools for plasma technology. The company has successfully raised a total of EUR 3.50 mn in funding through three deals, with the most recent being a Series B round on November 30, 2021, backed by investors including Applied Materials Europe BV, Enterprise Ireland, and SOSV. The current valuation of Impedans stands at EUR 13.865 mn. The company is led by co-CEOs David Gahan and Mike Hopkins.Impedans Ltd specializes in high-precision sensors and diagnostic solutions in plasma technology, catering to a diverse clientele that includes semiconductor manufacturers, university research institutes, and plasma equipment makers. Their core products encompass various advanced measurement tools, such as Langmuir probes for assessing fundamental plasma parameters, RF Voltage-Current (VI) probes for analyzing power and impedance, and the Semion series for substrate-level measurements and ion flux characterization. These products facilitate real-time monitoring and optimization of plasma processes across industries like semiconductor manufacturing, aerospace, and medical technology. By providing invaluable data on plasma behavior, Impedans's solutions enable their clients to enhance equipment performance, streamline production processes, and achieve specific application requirements. The company's offerings are sold globally, with a presence in key markets including North America, Europe, and Asia.Impedans Ltd engages in a business model that focuses on direct sales of its advanced diagnostic products to B2B clients, primarily within the semiconductor and plasma technology sectors. Their flagship products, including the Octiv VI probes and various Semion models, are critical in process development and equipment maintenance, forming the backbone of their sales strategy. The company reported an EBITDA of EUR -191,309.4 in 2015, indicating operational challenges. However, their revenue generation is structured around individual transactions for specific products, as well as potential recurring revenue through maintenance services and calibration solutions. Clients may also engage in partnerships for ongoing support and updates, ensuring that they can leverage the latest advancements in plasma diagnostics.Following the recent Series B funding round completed on November 30, 2021, where Impedans raised EUR 3.50 mn, the company plans to invest in the development of new products and expand into emerging markets. Upcoming products are aimed at enhancing precision in plasma diagnostics, though specific release dates are not yet disclosed. Impedans targets expansion into key markets in Asia and North America, anticipated to take place over the next two years, leveraging the recent funding to support these strategic initiatives.

## Funding rounds

- Series B, Nov 30, 2021, $4M — SOSV, Enterprise Ireland, Applied Materials Europe BV
- Series A, Feb 24, 2015, $0.6M — SOSV
- Seed, Jan 1, 2015 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed, Series A, Series B
- Enterprise Ireland (https://capitalatlas.ai/funds/enterprise-ireland) — Series B
- Applied Materials Europe BV — Series B